EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-Trypanosoma cruzi Activity, Mutagenicity, Hepatocytotoxicity and Nitroreductase Enzyme Evaluation of 3-Nitrotriazole, 2-Nitroimidazole and Triazole Derivatives

Cheyene Almeida Celestino Menozzi, Rodolfo Rodrigo Florido França iD, Pedro Henrique Luccas iD, Mayara Dos Santos Baptista, Tácio Vinício Amorim Fernandes, Lucas Villas Bôas Hoelz, Policarpo Ademar Sales Junior, Silvane Maria Fonseca Murta, Alvaro Romanha, Bárbara Verena Dias Galvão iD, Marcela de Oliveira Macedo, Alana da Cunha Goldstein und 5 weitere

Molecules · 2023

DOI: 10.3390/molecules28227461 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Cheyene Almeida Celestino Menozzi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Programa de Pós-Graduação em Farmacologia e Química Medicinal-PPGFQM-Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Bloco …. Hauptthemen laut MEDLINE: Trypanosoma cruzi, Trypanocidal Agents, Chagas Disease, Nitroimidazoles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, National Council for Scientific and Technological Development, São Paulo Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chagas disease (CD), which is caused by Trypanosoma cruzi and was discovered more than 100 years ago, remains the leading cause of death from parasitic diseases in the Americas. As a curative treatment is only available for the acute phase of CD, the search for new therapeutic options is urgent. In this study, nitroazole and azole compounds were synthesized and underwent molecular modeling, anti-T. cruzi evaluations and nitroreductase enzymatic assays. The compounds were designed as possible inhibitors of ergosterol biosynthesis and/or as substrates of nitroreductase enzymes. The in vitro evaluation against T. cruzi clearly showed that nitrotriazole compounds are significantly more potent than nitroimidazoles and triazoles. When their carbonyls were reduced to hydroxyl groups, the compounds showed a significant increase in activity. In addition, these substances showed potential for action via nitroreductase activation, as the substances were metabolized at higher rates than benznidazole (BZN), a reference drug against CD. Among the compounds, 1-(2,4-difluorophenyl)-2-(3-nitro-1H-1,2,4-triazol-1-yl)ethanol (8) is the most potent and selective of the series, with an IC50 of 0.39 µM and selectivity index of 3077; compared to BZN, 8 is 4-fold more potent and 2-fold more selective. Moreover, this compound was not mutagenic at any of the concentrations evaluated, exhibited a favorable in silico ADMET profile and showed a low potential for hepatotoxicity, as evidenced by the high values of CC50 in HepG2 cells. Furthermore, compared to BZN, derivative 8 showed a higher rate of conversion by nitroreductase and was metabolized three times more quickly when both compounds were tested at a concentration of 50 µM. The results obtained by the enzymatic evaluation and molecular docking studies suggest that, as planned, nitroazole derivatives may utilize the nitroreductase metabolism pathway as their main mechanism of action against Trypanosoma cruzi. In summary, we have successfully identified and characterized new nitrotriazole analogs, demonstrating their potential as promising candidates for the development of Chagas disease drug candidates that function via nitroreductase activation, are considerably selective and show no mutagenic potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Trypanosoma cruziTrypanocidal AgentsChagas DiseaseNitroimidazolesHumansStructure-Activity RelationshipMolecular Docking SimulationMutagensTriazolesNitroreductases

Stichwörter der Autor:innen

CYP51Chagas diseaseTrypanosoma cruziazoleheterocycleimidazolenitroreductasetriazole

Substanzen

MutagensTrypanocidal AgentsazomycinNitroimidazolesTriazolesNitroreductases

Autor:innen und Institutionen

  • Programa de Pós-Graduação em Farmacologia e Química Medicinal-PPGFQM-Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Bloco J, Ilha do Fundão, Rio de Janeiro 21941-902, Brazil.
  • Laboratório de Síntese de Fármacos-LASFAR, Instituto de Tecnologia em Fármacos, Fundação Oswaldo Cruz, Farmanguinhos-Fiocruz, Manguinhos, Rio de Janeiro 21041-250, Brazil.
  • Laboratório de Cristalografia de Proteínas-LCP-RP, Departamento de Ciências BioMoleculares, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo FCFRP-USP, Monte Alegre, Ribeirão Preto 14040-…
  • Centro de Pesquisas René Rachou/CPqRR-Fiocruz, Belo Horizonte 30190-009, Brazil.
  • Laboratório de Mutagênese Ambiental, Programa de Pós-Graduação em Biociências-PPGB-Instituto de Biologia Roberto Alcantara Gomes, Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20551-030, Brazil.
  • Programa de Pós-Graduação em Biologia Molecular e Celular-PPGBMC-Instituto Biomédico, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro 20211-010, Brazil.

ORCID-Profile: Rodolfo Rodrigo Florido França, Pedro Henrique Luccas, Bárbara Verena Dias Galvão, Carlos Fernando Araujo-Lima, Israel Felzenszwalb, Maria Cristina Nonato, Nubia Boechat

Förderung

  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
  • National Council for Scientific and Technological Development
  • São Paulo Research Foundation
  • Coordination of Superior Level Staff Improvement (CAPES)
  • Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (FAPERJ)
  • Foundation for Research Support of the State of São Paulo (FAPESP)

Zitieren

APA

Menozzi, C. A. C., França, R. R. F., Luccas, P. H., Baptista, M. D. S., Fernandes, T. V. A., Hoelz, L. V. B., Sales Junior, P. A., Murta, S. M. F., Romanha, A., Galvão, B. V. D., Macedo, M. O., Goldstein, A. D. C., Araujo-Lima, C. F., Felzenszwalb, I., Nonato, M. C., Castelo-Branco, F. S., & Boechat, N. (2023). Anti-Trypanosoma cruzi Activity, Mutagenicity, Hepatocytotoxicity and Nitroreductase Enzyme Evaluation of 3-Nitrotriazole, 2-Nitroimidazole and Triazole Derivatives. Molecules. https://doi.org/10.3390/molecules28227461

Vancouver

Menozzi CAC, França RRF, Luccas PH, Baptista MDS, Fernandes TVA, Hoelz LVB, et al. Anti-Trypanosoma cruzi Activity, Mutagenicity, Hepatocytotoxicity and Nitroreductase Enzyme Evaluation of 3-Nitrotriazole, 2-Nitroimidazole and Triazole Derivatives. Molecules. 2023. doi:10.3390/molecules28227461

BibTeX
@article{Menozzi2023,
  author = {Menozzi, Cheyene Almeida Celestino and França, Rodolfo Rodrigo Florido and Luccas, Pedro Henrique and Baptista, Mayara Dos Santos and Fernandes, Tácio Vinício Amorim and Hoelz, Lucas Villas Bôas and Sales Junior, Policarpo Ademar and Murta, Silvane Maria Fonseca and Romanha, Alvaro and Galvão, Bárbara Verena Dias and Macedo, Marcela de Oliveira and Goldstein, Alana da Cunha and Araujo-Lima, Carlos Fernando and Felzenszwalb, Israel and Nonato, Maria Cristina and Castelo-Branco, Frederico Silva and Boechat, Nubia},
  title = {Anti-Trypanosoma cruzi Activity, Mutagenicity, Hepatocytotoxicity and Nitroreductase Enzyme Evaluation of 3-Nitrotriazole, 2-Nitroimidazole and Triazole Derivatives},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28227461}
}
Kostenlos starten →